BOLT
Price
$4.08
Change
-$0.06 (-1.45%)
Updated
Oct 22 closing price
Capitalization
7.86M
20 days until earnings call
Intraday BUY SELL Signals
NRXP
Price
$2.40
Change
-$0.23 (-8.75%)
Updated
Oct 22 closing price
Capitalization
103.91M
22 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BOLT vs NRXP

BOLT vs NRXP Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BOLT vs. NRXP commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BOLT is a StrongBuy and NRXP is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BOLT with price predictions
Oct 22, 2026

BOLT in upward trend: price rose above 50-day moving average on October 09, 2026

BOLT moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 41 of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 64 of 77 cases where BOLT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on BOLT as a result. In 83 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for BOLT just turned positive on October 07, 2026. Looking at past instances where BOLT's MACD turned positive, the stock continued to rise in 41 of 46 cases over the following month. The odds of a continued upward trend are 89%.

The 10-day moving average for BOLT crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +5.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where BOLT advanced for three days, in 154 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

The Aroon Indicator entered an Uptrend today. In 80 of 92 cases where BOLT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.

Bearish Trend Analysis

The 10-day RSI Indicator for BOLT moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In 10 of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BOLT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

BOLT broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. BOLT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.622) is normal, around the industry mean (2.973). P/E Ratio (-0.247) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.355) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BOLT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for NRXP with price predictions
Oct 22, 2026

NRXP's Indicator enters downward trend

The Aroon Indicator for NRXP entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 297 similar instances where the Aroon Indicator formed such a pattern. In 289 of the 297 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for NRXP's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

NRXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NRXP's P/B Ratio (-611.234) is very low in comparison to the industry average of (2.973). P/E Ratio (-4.706) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (29.851) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. NRXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
NRXP: Fundamental Ratings
NRXP
OUTLOOK RATING
1..100
60
VALUATION
overvalued / fair valued / undervalued
1..100
1
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
80
P/E GROWTH RATING
1..100
12
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BOLTNRXP
RSI
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
N/A
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (BOLT: $4.14 vs. NRXP: $2.63)
Brand notoriety: BOLT and NRXP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BOLT: 157% vs. NRXP: 73%
Market capitalization -- BOLT: $7.86M vs. NRXP: $103.91M
BOLT [@Biotechnology] is valued at $7.86M. NRXP’s [@Biotechnology] market capitalization is $103.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BOLT’s FA Score shows that 1 FA rating(s) are green while NRXP’s FA Score has 2 green FA rating(s).

  • BOLT’s FA Score: 1 green, 4 red.
  • NRXP’s FA Score: 2 green, 3 red.
According to our system of comparison, BOLT is a better buy in the long-term than NRXP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BOLT’s TA Score shows that 7 TA indicator(s) are bullish while NRXP’s TA Score has 3 bullish TA indicator(s).

  • BOLT’s TA Score: 7 bullish, 3 bearish.
  • NRXP’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, BOLT is a better buy in the short-term than NRXP.

Price Growth

BOLT (@Biotechnology) experienced а +2.22% price change this week, while NRXP (@Biotechnology) price change was +1.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

BOLT is expected to report earnings on Nov 11, 2026.

NRXP is expected to report earnings on Nov 13, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BOLT
Daily Signal:
Gain/Loss:
NRXP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

BOLT and

Correlation & Price change

A.I.dvisor tells us that BOLT and XENE have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BOLT and XENE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BOLT
1D Price
Change %
BOLT100%
-1.45%
XENE - BOLT
31%
Poorly correlated
+1.53%
ARRY - BOLT
30%
Poorly correlated
-3.23%
NRXP - BOLT
29%
Poorly correlated
-8.75%
KRRO - BOLT
29%
Poorly correlated
+29.71%
SPRO - BOLT
28%
Poorly correlated
-3.42%
More

NRXP and

Correlation & Price change

A.I.dvisor indicates that over the last year, NRXP has been closely correlated with TAOX. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if NRXP jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRXP
1D Price
Change %
NRXP100%
-8.75%
TAOX - NRXP
84%
Closely correlated
-5.50%
ALLR - NRXP
81%
Closely correlated
-2.73%
PALI - NRXP
74%
Closely correlated
-3.57%
COYA - NRXP
35%
Loosely correlated
N/A
ACET - NRXP
34%
Loosely correlated
-4.68%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LQDM23.250.20
+0.87%
Amplify LQD Investment Grade 12% Target Income ETF (LQDM)
ZMUN49.920.08
+0.17%
F/m Ultrashort Tax-Free Municipal ETF (ZMUN)
EAD5.91-0.04
-0.67%
Allspring Income Opportunities Fund
ARKG47.87-1.98
-3.97%
ARK Genomic Revolution ETF (ARKG)
SMCX8.74-1.00
-10.27%
Defiance Daily Target 2X Long SMCI ETF (SMCX)